European Vaccine Markets: Germany, UK, France, Spain Italy, Rest of Europe

Report Summary

The European vaccines market has demonstrated growth even through tough economic times. This has mainly been due to the introduction of vaccines in untapped disease markets and government's acceptance and willingness to pay for new products. This has encouraged market participants to increase spending in research and development.

This report, European Vaccine Markets, examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer's disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attack, Helicobacter pylori infection, multiple sclerosis, Parkinson's disease, West Nile virus (WNV) infection, etc.; vaccines that address these conditions are discussed in Kalorama's new report, "Emerging Vaccines: The World Market." The report includes vaccine market stats for:

• Adult Vaccines-Estimates and Forecasts for
• Influenza
• Pneumococcal
• Meningitis/Pneumonia
• DTaP
• Hepatitis
• HPV
• Travel and Endemic
• Others
• Pediatric Vaccines-Estimates and Forecasts for:
• Haemophilus influenzae type b (Hib)
• Pneumococcal infection
• Diphtheria
• Tetanus
• Pertussis (whooping cough)
• Hepatitis A and B
• Rotavirus
• Polio
• Measles
• Mumps and Rubella
• Varicella (chicken pox)
• Influenza
• Meningitis
• Human papillomavirus (HPV)
• Combination Vaccines
• Others

The report also contains adult and pediatric vaccine regional market shares for the following countries:

• United Kingdom
• Germany
• Spain
• France
• Italy
• Rest of Europe

n this Kalorama Information Report "Rest of Europe" is broken down in the total market summary (adult and pediatric combined) to include regional market share of the total European Vaccine market for Benelux, Scandinavia, Switzerland, Russia, Poland, Balkans, Baltic Countries, Hungary and Other
The report also includes company market shares for European adult and pediatric vaccine markets, key issues and trend affecting the industry, and detailed profiles of major vaccine competitors, including:

• Bavarian Nordic A/S
• Baxter International
• Crucell
• Emergent Biosolutions
• GlaxoSmithKline
• Novartis
• Pfizer Inc.
• Sanofi Pasteur

All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.

In 2009, the adult flu vaccine market in Europe reached new heights with nearly $1.6 billion in revenues, up 81.4% from the prior year. According to healthcare market research publisher Kalorama Information's newly published European Vaccine Markets, this surge in flu vaccine sales was due to products developed to address the H1N1 flu pandemic.

Influenza vaccines are responsible for almost half of the adult vaccine market in 2010. Although Kalorama does not foresee the same kind of growth witnessed in 2009, the publisher expects strong demand for flu vaccines to continue, supported by an aging population and expanded recommendations for adult influenza vaccinations, though tempered by a near term decrease in demand for pandemic vaccines.

"The swine flu pandemic of 2009 prompted a flurry of activity in the flu vaccines market around the world, with a resulting surge in revenues," says Bruce Carlson, publisher of Kalorama Information. "This growth is unlikely to continue as governments overestimated the demand for H1N1 flu vaccines and found themselves with excess stock. Current development initiatives focus on products that protect against pandemic outbreaks, specific strains of influenza and alternative administration routes."

In May 2008, GlaxoSmithKline received European approval for Prepandrix and Pandemrix; each contains the H5N1 (avian flu) inactivated split, monovalent virus. Prepandrix is designed to be given before or at the onset of a declared influenza pandemic to prevent influenza caused by H5N1. It is formulated with a novel proprietary adjuvant system, which is designed to achieve a high immune response at a low dose of antigen, and to be long-lasting and active against a broad range of H5N1 strains. Pandemrix is approved for use when an H5N1 influenza pandemic has been officially declared by the WHO or European Union.
In December 2008, the European Medicines Agency (EMEA) issued a positive opinion for Baxter's CELVAPAN, the first cell culture-based H5N1 pandemic vaccine, in the European Union. CELVAPAN is made using Baxter's proprietary Vero cell technology, which speeds up the manufacturing process due to its ability to use the native virus which does not need to be modified in order to grow in chicken eggs. The shorter production time is critical in accelerating vaccine supply in response to an influenza pandemic.

Also of note are advancing efforts to develop a universal flu vaccine which would protect against multiple influenza strains, thereby significantly increasing effectiveness. While many companies over the years have investigated methods to achieve this, U.K.-based Immune Targeting Systems, with funding from a broad range of investors including Novartis's venture capital group, is expected to begin studies of a product candidate in 2010.

More information on flu and other types of vaccines in the European market can be found in Kalorama Information's European Vaccine Markets. This report presents market estimates and forecasts, product reviews and pipelines, issues and trends, and company profiles for pediatric and adult vaccines.

TABLE OF CONTENTS

CHAPTER ONE: EXECUTIVE SUMMARY

THE EUROPEAN VACCINES MARKET
Scope and Methodology
Overview
Pediatric Preventative Vaccines
Adult Preventative Vaccines
Total Market
Issues and Trends

CHAPTER TWO: INTRODUCTION TO VACCINES
A Brief History: The Development of Vaccines
The Immune Response
Mechanism of Action
Types of Vaccines
Attenuated (Weakened) Live Viruses
Killed (Inactivated) Viruses
Toxoid Vaccines
Genetically Engineered/Modified Vaccines
Subunit Vaccines
Conjugate Vaccines
DNA Vaccination
Vaccine Approval Process

CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES
Introduction
United Nations Initiatives
Pediatric Vaccine Products
BCG
Diphtheria, Tetanus, Pertussis, Hepatitis B and Polio
Diphtheria
Pertussis
Tetanus
Hepatitis B
Poliomyelitis
Haemophilus Influenzae Type B
Hepatitis A
Measles, Mumps and Rubella
Measles
Mumps
Rubella
Meningococcal Disease
Pneumococcal Conjugate
Rotavirus
Varicella
Pediatric Vaccines in Development
The European Market for Pediatric Preventive Vaccines
Total European Market Size and Forecast
European Market by Product Type
Haemophilus Influenzae Type B (Hib)
Pneumococcal
DTaP
Hepatitis A & B
Rotavirus
Polio
MMR
Varicella
Influenza
Menigococcal
HPV
Combinations
Others
Major Manufacturer’s Market Share—Pediatric Vaccines

CHAPTER FOUR: ADULT PREVENTIVE VACCINES
Introduction
Adult Vaccine-Preventable Diseases: Facts and Figures
Recommendations for Adult Immunization
WHO International Health Regulations
Adult Vaccine Products
BCG
Cervical Cancer
Cholera
Diphtheria-Tetanus
Hepatitis
Hepatitis A
Hepatitis B
Influenza
Pneumococcal Disease
Rabies
Shingles
Typhoid Fever
Adult Vaccines in Development
The European Market for Adult Preventive Vaccines
Total European Market Size and Forecast
European Market by Product Type
Influenza
DTaP Booster
HPV
Hepatitis
Meningitis/Pneumonia
Travel/Endemic Vaccines
Others
Major Manufacturer’s Market Share—Adult Vaccines

CHAPTER FIVE: VACCINES MARKET SUMMARY
Trends Driving the Vaccines Market
Market Size and Forecast
Vaccine Sales by Region
Vaccine Market Competitors

CHAPTER SIX: ISSUES AND TRENDS
Vaccine Safety
Refusal to Immunize
Obesity
World Health Organization
The Future of Vaccine Safety
Vaccine Shortages
Financial incentives
Equitable pricing
Vaccine stockpiles
Smallpox
Tularemia
Viral Hemorrhagic Fevers
DNA Vaccination
Innovations in Vaccine Delivery Systems
Edible Vaccines
Mucosal Delivery
Intranasal Delivery
Vaccine Patches
Vaccine Chips
Innovations in Vaccine Production
Tobacco Plant
Insects
Nanoparticle Systems

CHAPTER SEVEN: COMPANY PROFILES
Bavarian Nordic A/S
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Baxter International
History and Lines of Business
Vaccine Products
Financial Information
Crucell
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Emergent Biosolutions
History and Lines of Business
Strategic Acquisition and Alliance
Vaccine Products
Financial
GlaxoSmithKline
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Novartis
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information
Pfizer Inc.
History and Lines of Business
Strategic alliances
Vaccine Products
Financial Information
Sanofi Pasteur
History and Lines of Business
Strategic Alliances
Vaccine Products
Financial Information

COMPANY DIRECTORY

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: Estimated Market Sizes for Preventive Vaccines by Target Age Group in Europe 2006 - 2014
Table 1-2:Estimated Market Sizes for Preventive Vaccines in Europe 2006 - 2014

CHAPTER TWO: INTRODUCTION TO VACCINES

Table 2-1: Impact of Vaccines in the 20th Century Annual Morbidity in the 20th Century vs 2009 (United States)
Table 2-2: 1Impact of Vaccines in Europe Annual Incidence 1985 vs 2008
Table 2-3: Vaccine-Preventable Diseases, June 2010

CHAPTER THREE: PEDIATRIC PREVENTIVE VACCINES

Table 3-1: Global Immunization Rates by Vaccine Type 2008 (DPT3, BCG, HepB, Hib, Measles, Polio)
Table 3-2: Selected Pediatric Vaccines in Development
Table 3-2: Selected Pediatric Vaccines in Development
Table 3-3: Estimated Market Sizes for Pediatric Preventive Vaccines in Europe 2006 - 2014
Figure 3-1: Estimated Market Sizes for Pediatric Preventive Vaccines in Europe 2006 - 2014
Table 3-4: Estimated Market Sizes for Pediatric Preventive Vaccines by Type in Europe (Hib Pneumococcal, DTaP, Hepatitis B, Rotavirus, Polio, MMR, Varicella, Hepatitis A, Influenza, Menigococcal, HPV, Combinations, Others, ) 2006 - 2014
Figure 3-2: Estimated Market Sizes for Pediatric Preventive Vaccines by Type in Europe, by Percent (Hib Pneumococcal, DTaP, Hepatitis B, Rotavirus, Polio, MMR, Varicella, Hepatitis A, Influenza, Menigococcal, HPV, Combinations, Others, ) , 2010
Figure 3-3: Major Manufacturers’ Shares of the Pediatric European Preventive Vaccine Market, 2010
Table 3-5: 2010 European Pediatric Vaccines Market Share, by Leading Competitors

CHAPTER FOUR: ADULT PREVENTIVE VACCINES

Table 4-1: Universal Adult Immunization Schedule 2010
Table 4-2: Adult Immunization Schedule for Populations with Special Medical Conditions, 2010
Table 4-3: WHO Pandemic Classification Schedule
Table 4-4: Selected Adult Preventive Vaccines in Development, 2010
Table 4-5: Estimated Market Sizes for Adult Preventive Vaccines in Europe 2006 - 2014
Figure 4-2: Estimated Market Sizes for Adult Preventive Vaccines in Europe 2006 - 2014
Table 4-6: Estimated Market Sizes for Adult Preventive Vaccines by Type in Europe, by Percent(Influenza, Pneumococcal/ Meningitis/Pneumonia, DTaP, Hepatitis, HPV, Travel and Endemic, Others), 2010
Table 4-7: Major Manufacturer’s Market Share—Adult Vaccines
Table 4-8: Major Manufacturers’ Shares of the Adult European Preventive Vaccine Market, 2010
Figure 4-3: 2010 European Adult Vaccines Market Share, by Leading Competitors

CHAPTER FIVE: VACCINES MARKET SUMMARY

Table 5-1: Estimated Market Sizes for Preventive Vaccines by Target Age Group in Europe 2006 - 2014
Figure 5-1: Estimated Market Sizes for Preventive Vaccines in Europe 2006 - 2014
Figure 5-2: European Market for Vaccines Share by Type, 2006, 2010 and 2014
Figure 5-3: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines by European Region 2006 - 2014
Table 5-2: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines by European Region 2006 - 2014
Figure 5-4: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines by European Region, by Percent, 2010
Figure 5-5: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines: Top Five Countries versus Other Regions in Europe, by Percent, 2010
Figure 5-6: Estimated Market Sizes for Adult and Pediatric Preventive Vaccines: Top Five Countries versus Other Regions in Europe, by Percent, 2010
Table 5-3: Major Manufacturers’ Shares of the Total European Preventive Vaccine Market, 2010
Figure 5-7: 2010 European Vaccines Market Share, by Leading Competitors